Microbot Medical Announces First Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds

Rhea-AI Summary

Microbot Medical (Nasdaq: MBOT) announced the first closing of its preferred investment options exercise, which could generate up to $92.2 million in total gross proceeds. The transaction includes $25.2 million from the first closing and expected $4 million from the second closing, with potential additional proceeds of $63 million if new short-term series J preferred investment options are fully exercised.

The first closing involves 12,064,627 shares at exercise prices of $1.50-$2.13 per share, while the second closing will include 1,924,488 shares at $2.10 per share. New series J options will have a $4.50 exercise price. Proceeds will fund the LIBERTY® Robotic System development, potential acquisitions, and working capital.

Positive

• None.

Negative

• Significant dilution due to issuance of over 13.9 million new shares
• No guarantee that the $63 million in additional options will be exercised
• Second closing of $4 million still subject to closing conditions

Insights

Financial Analyst

Microbot secured $25.2M in first-round financing with potential for up to $92.2M total, significantly strengthening its financial position for LIBERTY® Robotic System commercialization.

Microbot Medical has successfully executed a significant capital raise through a structured preferred investment options exercise. The company secured $25.2 million in the first closing and expects $4 million in a second closing by October 15, 2025, with potential for an additional $63 million if all new short-term Series J options are exercised.

This financing represents a substantial cash infusion for Microbot, effectively quadrupling their capital reserves compared to their last reported cash position. The transaction structure is particularly favorable as it involves the exercise of existing options at prices ranging from $1.50 to $2.13 per share, which are significantly below the company's current trading price.

In exchange for exercising these options, holders received new unregistered Series J options with an exercise price of $4.50 per share - representing a premium of over 100% to the original option prices. This structure not only brings immediate capital but creates potential for additional significant funding if the company's prospects improve further, as the Series J options become exercisable after six months.

The capital infusion arrives at a critical juncture for Microbot as they advance their LIBERTY® Robotic System toward commercialization. The proceeds provide crucial runway for regulatory activities and development work, potentially accelerating their path to market and reducing the likelihood of near-term dilutive financing. The company's mention of potential acquisitions suggests management is considering strategic growth opportunities that could expand their technology portfolio beyond their current robotic system.

$25.2 million in first closing and $4 million in second closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in full of short-term preferred investment options

HINGHAM, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) (“Microbot” or the “Company”), today announced the first closing of its previously announced exercise of certain outstanding preferred investment options to purchase up to an aggregate of 13,989,115 shares of common stock. The shares of common stock issuable upon exercise of the preferred investment options are registered pursuant to the post-effective amendments on Form S-3 to registration statements on Form S-1 (File Nos. 333-280113 and 333-284688) and registration statement on Form S-3 (File No. 333-285690).

The closing of the offering is expected to occur in two tranches. At the first closing, the holders exercised certain outstanding preferred investment options to purchase up to an aggregate of 12,064,627 shares of common stock, having exercise prices ranging from $1.50 to $2.13 per share, issued by Microbot in June 2024, January 2025 and February 2025, and in consideration for the exercise of the preferred investment options for cash, Microbot issued to such holders new unregistered short-term series J preferred investment options to purchase up to 12,064,627 shares of common stock. The second closing of the offering is expected to occur by no later than October 15, 2025, subject to satisfaction of customary closing conditions. At the second closing, a holder will exercise certain outstanding preferred investment options to purchase up to an aggregate of 1,924,488 shares of common stock, having an exercise price of $2.10 per share, issued by Microbot in January 2025, and in consideration for the exercise of the preferred investment options for cash, Microbot will issue to such holder new unregistered short-term series J preferred investment options to purchase up to 1,924,488 shares of common stock. The new short-term series J preferred investment options will have an exercise price of $4.50 per share, will be exercisable beginning six months after issuance and have a term equal to two years thereafter.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The gross proceeds to the Company were approximately $25.2 million from the first closing of the offering and are expected to be approximately $4 million from the second closing of the offering, in each case prior to deducting placement agent fees and offering expenses. The potential additional gross proceeds to the Company from the short-term series J preferred investment options, if fully-exercised on a cash basis, will be approximately $63 million.  No assurance can be given that any of such short-term series J preferred investment options will be exercised.  The Company intends to use the net proceeds from the offering for the continued development, commercialization and regulatory activities for the Company’s LIBERTY^® Robotic System, potential acquisitions of complementary assets or products, expansion and development of additional applications derived from the Company’s existing IP portfolio, and for working capital and other general corporate purposes.

The new short-term series J preferred investment options described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the “1933 Act”), and, along with the shares of common stock issuable upon exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. Microbot has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new short-term series J preferred investment options.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a breakthrough medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY^® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

Safe Harbor
Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, the completion of the second closing of the offering, the satisfaction of customary closing conditions related to the second closing of the offering, the exercise of the unregistered short-term series J preferred investment options prior to their expiration, the intended use of proceeds from the offering, the Company’s need for and ability to obtain additional working capital to continue its transition to a commercially focused company, market conditions, risks inherent in the commercialization of the LIBERTY^® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical^® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical^® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:

IR@microbotmedical.com
Media@microbotmedical.com

FAQ

How much money is Microbot Medical (MBOT) raising in its preferred investment options exercise?

Microbot Medical is raising $25.2 million in the first closing and expects $4 million in the second closing, with potential additional proceeds of $63 million if all new series J options are exercised, totaling up to $92.2 million.

What is the exercise price for MBOT's new series J preferred investment options?

The new series J preferred investment options have an exercise price of $4.50 per share and will be exercisable beginning six months after issuance with a two-year term thereafter.

How will Microbot Medical use the proceeds from this offering?

The proceeds will be used for LIBERTY® Robotic System development and commercialization, potential acquisitions of complementary assets, expansion of IP portfolio applications, and working capital.

When will MBOT's second closing of the offering take place?

The second closing is expected to occur by October 15, 2025, subject to satisfaction of customary closing conditions.

How many shares are being issued in MBOT's preferred investment options exercise?

The offering includes 12,064,627 shares in the first closing and 1,924,488 shares in the second closing, totaling 13,989,115 shares of common stock.